Andrew Gallagher

About
Latest Posts

Andrew Gallagher is chief operating officer at Phynova, a British life science company that develops and sells medically licensed drugs, functional ingredients and cosmeceuticals derived from active compounds found in plants.

Latest posts by Andrew Gallagher (see all)

Licensing traditional Chinese medicines - 15th September 2016

Licensing traditional Chinese medicines

Coronavirus, COVID-19 Update, Infection/Disease
ECMO has positive impact on survival rates
ECMO has positive impact on survival rates: Analysis of the critical care of Covid-19 patient involving the use of extracorporeal membrane oxygenation (ECMO) in University Hospital Vienna shows that the …
Coronavirus, COVID-19 Update, Infection/Disease
One year of SARS-CoV-2 mutations
Researchers have published an in-depth look at the SARS-CoV-2 mutations that have taken place during the past year in the Journal of General Virology. The review discusses the findings of over 180 research …
Diabetes, Global Reach
Homeless facing diabetes crisis
Research reveals homeless people facing diabetes crisis New research, presented at DUKPC 2021, finds that globally, up to 22% of people experiencing homelessness have some form of diabetes Over 40% …
COVID-19 Update, Mental Health, Paediatrics, Psychology, Royal Society of Medicine
Mental health in schools and colleges: the …
Transforming mental health in schools and colleges: the impact of COVID-19: Royal Society of Medicine conference: Thursday 22 April, online, 10.00am to 5.30pm Clinicians, researchers, teachers, parents, and young people will gather at …
Cancer, Coronavirus, COVID-19 Update
UK Covid-19: Cancer patients more likely to …
Cancer patients from the UK were 1.5 times more likely to die following a diagnosis with COVID-19 than cancer patients from European countries. This is the finding of a study …

The Royal Society of Medicine blogs

View all posts from The RSM »

LATEST: Mental health in schools and colleges: the impact of COVID-19